SAB Biotherapeutics, Inc. (SABS) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 5 Buy, 1 Hold.
The consensus price target is $7.00, representing an upside of 81.3% from the current price $3.86.
Analysts estimate Earnings Per Share (EPS) of $-3.68 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.68 vs est $-3.68 (beat +0%). 2025: actual $0.22 vs est $-0.41 (beat +153.4%). Analyst accuracy: 0%.
SABS Stock — 12-Month Price Forecast
$7.00
▲ +81.35% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for SAB Biotherapeutics, Inc., the price target is $7.00.
The average price target represents a +81.35% change from the last price of $3.86.
SABS Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to SAB Biotherapeutics, Inc. in the past 3 months
EPS Estimates — SABS
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3.68
vs Est –$3.68
▼ 0.0% off
2025
Actual $0.22
vs Est –$0.41
▲ 287.1% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — SABS
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 0.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
